蛇毒抗栓酶Ⅲ号对肺心病急性发作期疗效分析

Analysis of the Effectiveness of SVATE-3 Treatment on Acute Attack Phase of Pulmonary Heart Disease

对肺心病急性发作期患者联合使用蛇毒抗栓酶Ⅲ号和常规疗法进行治疗，并与单纯常规疗法作对照。结果表明蛇毒组的部分缓解所需天数明显少于对照组（P＜0．01），组织型纤溶酶原激活物（tpA）含量明显高于对照组（P＜0．01），血浆丙二醛水平明显低于对照组（P＜0．05），血液流变学和血气分析的多项指标改善也优于对照组。提示蛇毒抗栓酶可能通过提高tpA含量纠正高凝状态和纤溶功能低下，使基础治疗更能发挥作用。

Patients with Pulmonary heart disease during acute attack phase were treated with snake venom antithrombotic enzyme-3 (SVATE-3) beside routine treatment, were compared with patients treated by routine therapy alone as control. The results showed that in the combined therapy group, the days for partial remission were obviously less than that of control group (P < 0. 01 ), the contents of tissue - Plasminogen activator (tPA) was obviously higher than that in control group (P< 0. 01 ). and the concentration of plasma MDA was Obviously lower than that of control group (p< 0.05). Many indices of blood rheology and hlood gas analysis was showd improvement and better than that of the control group. It was showed that SVATE-3 could correct hypercoagulability and improve fibrinolysis function by raising the contents of tPA, thus it could improve the basal treatment.